Recommended INN - List 65
rINN
brentuximab vedotin
drozitumab
dulaglutide
elpamotide
ensituximab
foralumab
ganitumab
insulin tregopil
itolizumab
lorvotuzumab mertansine
nonacog beta pego
olaratumab
olokizumab
oxelumab
peginesatide
roledumab
samalizumab
somatropin pegol
tiprelestat
trastuzumab emtansine
▲
